Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History LVTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics LVTX

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

LAVA Therapeutics NV

LVTX
Current price
1.42 USD -0.01 USD (-0.70%)
Last closed 1.40 USD
ISIN NL0015000AG6
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 36 827 420 USD
Yield for 12 month -29.70 %
1Y
3Y
5Y
10Y
15Y
LVTX
21.11.2021 - 28.11.2021

LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. The company has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is based in Utrecht, the Netherlands. Address: Yalelaan 62, Utrecht, Netherlands, 3584 CM

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

1.92 USD

P/E Ratio

Dividend Yield

Financials LVTX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures LVTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+11 982 000 USD

Last Year

+6 769 000 USD

Current Quarter

Last Quarter

+4 990 000 USD

Current Year

+11 515 000 USD

Last Year

+3 287 000 USD

Current Quarter

Last Quarter

+4 990 000 USD
EBITDA -30 915 000 USD
Operating Margin TTM -628.16 %
Price to Earnings
Return On Assets TTM -23.02 %
PEG Ratio
Return On Equity TTM -73.21 %
Wall Street Target Price 1.92 USD
Revenue TTM 4 990 000 USD
Book Value 0.98 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 1 313.60 %
Dividend Yield
Gross Profit TTM -19 560 000 USD
Earnings per share -1.05 USD
Diluted Eps TTM -1.05 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation LVTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2.12
Price Sales TTM 7.38
Enterprise Value EBITDA 0.81
Price Book MRQ 1.51

Technical Indicators LVTX

For 52 Weeks

0.85 USD 2.21 USD
50 Day MA 1.31 USD
Shares Short Prior Month 64 545
200 Day MA 1.33 USD
Short Ratio 1.66
Shares Short 57 807
Short Percent 0.40 %